Annual Cervical Cancer Screening Revealed Early Stage Clear Cell Adenocarcinoma of the Uterine Cervix: A Case Report

2019 ◽  
Vol 8 (1) ◽  
pp. 21-24
Author(s):  
Mai Temukai ◽  
Yoshimi Tokugawa ◽  
Takeshi Hisamatsu ◽  
Yuri Kamino ◽  
Ayuko Otoshi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Case Report ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Uterine Cervix ◽  
Clear Cell ◽  
Early Stage ◽  
Clear Cell Adenocarcinoma

Can we substitute brush cytology for biopsy in the evaluation of cervical lesions under the guidance of colposcopy?

2005 ◽  
Vol 15 (3) ◽  
pp. 489-492
Author(s):  
Z. Eftekhar ◽  
N. Izadi-Mood ◽  
F. Yarandi ◽  
M. Khodamoradi ◽  
P. Rahimi-Moghaddam
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Standard Method ◽  
Uterine Cervix ◽  
Gold Standard ◽  
Brush Cytology ◽  
Cervical Lesions ◽  
Gold Standard Method ◽  
Special Expertise

In cervical cancer screening, colposcopically directed biopsy is the gold standard method for identifying intraepithelial and occult invasive lesions of the uterine cervix. As biopsy needs special expertise and the procedure is not convenient for the patients, we sought to evaluate colposcopically directed brush cytology as a substitute for biopsy of cervical lesions. We studied a series of 150 women who were referred for colposcopic evaluation. Colposcopically directed brush cytology and biopsy were performed for all patients with abnormal colposcopic findings. A total of 40 samples were excluded due to unsatisfactory report of brush cytology. Of the remaining 110 samples, 34 abnormal pathologies were reported in biopsy evaluations, while only 9 abnormal cytologies were reported in brush cytology specimens. Brush cytology sensitivity and specificity were 26% and 97%, respectively. We conclude that colposcopically directed brush cytology is not a safe substitute for biopsy in the evaluation of cervical lesions.

scholarly journals Barriers and Challenges to Treatment Alternatives for Early-Stage Cervical Cancer in Lower-Resource Settings

2017 ◽  
Vol 3 (5) ◽  
pp. 572-582 ◽  
Author(s):  
Emily S. Wu ◽  
Jose Jeronimo ◽  
Sarah Feldman
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Early Stage ◽  
Human Papillomavirus Vaccination ◽  
Financial Barriers ◽  
Screening Programs ◽  
The World ◽  
Early Stage Cervical Cancer ◽  
Barriers And Challenges

Cervical cancer is one of the most common cancers among women worldwide, and approximately 85% of new diagnoses occur in less-developed regions of the world. Global efforts in cervical cancer to date have focused on primary and secondary prevention strategies of human papillomavirus vaccination and cervical cancer screening. Cervical cancer screening is effective to reduce the incidence of cervical cancer and can result in diagnosis at earlier stages, but it will take time to realize its full impact. With expansion of screening programs, there is now a greater imperative to increase access to treatment for women who have cervical cancer, particularly in earlier stages of disease, when it is still curable. Resources for multimodality treatment can be limited—or even absent—in many less-developed regions of the world and may be associated with geographic, social, and financial barriers for the patient. However, there is evidence that, in many cases, less-invasive and less–resource-intensive treatment options are still effective. To this end, the National Comprehensive Cancer Network and American Society of Clinical Oncology have published guideline adaptations for specific resource constraints, and research about more conservative approaches to the treatment of cervical cancer continues. This review focuses on potential barriers and challenges to provision of safe and effective treatment of early-stage cervical cancer in lower-resource settings, and it suggests future directions for expansion of access to cervical cancer treatment around the world.

scholarly journals Clear cell adenocarcinoma of the uterine cervix: a case report.

1993 ◽  
Vol 32 (1) ◽  
pp. 91-92
Author(s):  
Toshiyuki SHIGEMATSU ◽  
Masashi IMACHI ◽  
Takae FUJIWARA ◽  
Naoki TSUKAMOTO ◽  
Hitoo NAKANO
Keyword(s):  
Case Report ◽  
Uterine Cervix ◽  
Clear Cell ◽  
Clear Cell Adenocarcinoma
Sign in / Sign up

Export Citation Format

Share Document